69 related articles for article (PubMed ID: 11185965)
21. Use of radiolabeled 2-methylthio-ADP to study P2Y receptors on platelets and cell lines.
Savi P; Herbert JM
Methods Mol Biol; 2004; 273():115-24. PubMed ID: 15308797
[No Abstract] [Full Text] [Related]
22. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.
Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM
Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514
[TBL] [Abstract][Full Text] [Related]
23. Regulation of P2Y1 receptor-mediated signaling by the ectonucleoside triphosphate diphosphohydrolase isozymes NTPDase1 and NTPDase2.
Alvarado-Castillo C; Harden TK; Boyer JL
Mol Pharmacol; 2005 Jan; 67(1):114-22. PubMed ID: 15496502
[TBL] [Abstract][Full Text] [Related]
24. Adenosine triphosphate is full antagonist at human P2Y(1) purinoceptors.
Sak K; Järv J
Neurosci Lett; 2000 Apr; 284(3):179-81. PubMed ID: 10773428
[TBL] [Abstract][Full Text] [Related]
25. P2Y1 receptors mediate inhibitory purinergic neuromuscular transmission in the human colon.
Gallego D; Hernández P; Clavé P; Jiménez M
Am J Physiol Gastrointest Liver Physiol; 2006 Oct; 291(4):G584-94. PubMed ID: 16751171
[TBL] [Abstract][Full Text] [Related]
26. 5-OMe-UDP is a potent and selective P2Y(6)-receptor agonist.
Ginsburg-Shmuel T; Haas M; Schumann M; Reiser G; Kalid O; Stern N; Fischer B
J Med Chem; 2010 Feb; 53(4):1673-85. PubMed ID: 20095577
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory purinergic P2 receptor characterisation in rat distal colon.
Van Crombruggen K; Van Nassauw L; Timmermans JP; Lefebvre RA
Neuropharmacology; 2007 Aug; 53(2):257-71. PubMed ID: 17612577
[TBL] [Abstract][Full Text] [Related]
28. CysLT1 receptor is a target for extracellular nucleotide-induced heterologous desensitization: a possible feedback mechanism in inflammation.
Capra V; Ravasi S; Accomazzo MR; Citro S; Grimoldi M; Abbracchio MP; Rovati GE
J Cell Sci; 2005 Dec; 118(Pt 23):5625-36. PubMed ID: 16306225
[TBL] [Abstract][Full Text] [Related]
29. P2Y1 receptor-mediated glutamate release from cultured dorsal spinal cord astrocytes.
Zeng JW; Liu XH; Zhang JH; Wu XG; Ruan HZ
J Neurochem; 2008 Sep; 106(5):2106-18. PubMed ID: 18627435
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and P2Y receptor activity of nucleoside 5'-phosphonate derivatives.
Cosyn L; Van Calenbergh S; Joshi BV; Ko H; Carter RL; Kendall Harden T; Jacobson KA
Bioorg Med Chem Lett; 2009 Jun; 19(11):3002-5. PubMed ID: 19419868
[TBL] [Abstract][Full Text] [Related]
31. Identification of an ecto-nucleoside diphosphokinase and its contribution to interconversion of P2 receptor agonists.
Lazarowski ER; Homolya L; Boucher RC; Harden TK
J Biol Chem; 1997 Aug; 272(33):20402-7. PubMed ID: 9252347
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of uracil nucleotide analogs with a modified, acyclic ribose moiety as P2Y(2) receptor antagonists.
Sauer R; El-Tayeb A; Kaulich M; Müller CE
Bioorg Med Chem; 2009 Jul; 17(14):5071-9. PubMed ID: 19523835
[TBL] [Abstract][Full Text] [Related]
33. Nucleotides-Induced Changes in the Mechanical Properties of Living Endothelial Cells and Astrocytes, Analyzed by Atomic Force Microscopy.
Gil-Redondo JC; Iturri J; Ortega F; Pérez-Sen R; Weber A; Miras-Portugal MT; Toca-Herrera JL; Delicado EG
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435130
[TBL] [Abstract][Full Text] [Related]
34. GPR17: molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors.
Parravicini C; Ranghino G; Abbracchio MP; Fantucci P
BMC Bioinformatics; 2008 Jun; 9():263. PubMed ID: 18533035
[TBL] [Abstract][Full Text] [Related]
35. Kinetic analysis of [35S]dATP alpha S interaction with P2y(1) nucleotide receptor.
Oras A; Kilk K; Kunapuli S; Barnard EA; Järv J
Neurochem Int; 2002 Apr; 40(5):381-6. PubMed ID: 11821144
[TBL] [Abstract][Full Text] [Related]
36. An arginine/glutamine difference at the juxtaposition of transmembrane domain 6 and the third extracellular loop contributes to the markedly different nucleotide selectivities of human and canine P2Y11 receptors.
Qi AD; Zambon AC; Insel PA; Nicholas RA
Mol Pharmacol; 2001 Dec; 60(6):1375-82. PubMed ID: 11723245
[TBL] [Abstract][Full Text] [Related]
37. Defining the nucleotide binding sites of P2Y receptors using rhodopsin-based homology modeling.
Ivanov AA; Costanzi S; Jacobson KA
J Comput Aided Mol Des; 2006; 20(7-8):417-26. PubMed ID: 17016747
[TBL] [Abstract][Full Text] [Related]
38. The synthesis and initial characterization of an immobilized purinergic receptor (P2Y1) liquid chromatography stationary phase for online screening.
Moaddel R; Calleri E; Massolini G; Frazier CR; Wainer IW
Anal Biochem; 2007 May; 364(2):216-8. PubMed ID: 17391632
[No Abstract] [Full Text] [Related]
39. Nucleotide analogues containing 2-oxa-bicyclo[2.2.1]heptane and l-alpha-threofuranosyl ring systems: interactions with P2Y receptors.
Ohno M; Costanzi S; Kim HS; Kempeneers V; Vastmans K; Herdewijn P; Maddileti S; Gao ZG; Harden TK; Jacobson KA
Bioorg Med Chem; 2004 Nov; 12(21):5619-30. PubMed ID: 15465340
[TBL] [Abstract][Full Text] [Related]
40. Kinetics of [35S]dATPalphaS interaction with P2Y1 purinoceptor in rat brain membranes.
Oras A; Järv J
Neurosci Lett; 2004 Jan; 355(1-2):9-12. PubMed ID: 14729222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
